WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997035603) CYCLOSPORIN A FORMULATIONS AS NANOPARTICLES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/035603    International Application No.:    PCT/US1997/004627
Publication Date: 02.10.1997 International Filing Date: 21.03.1997
IPC:
A61K 9/10 (2006.01), A61K 9/48 (2006.01), A61K 38/13 (2006.01), A61K 47/10 (2006.01), A61K 47/14 (2006.01), A61K 47/26 (2006.01)
Applicants: SANGSTAT MEDICAL CORPORATION [US/US]; 1505-B Adams Drive, Menlo Park, CA 94025 (US) (For All Designated States Except US).
FLOC'H, Robert [FR/FR]; (FR) (For US Only).
MERLE, Christian [FR/FR]; (FR) (For US Only)
Inventors: FLOC'H, Robert; (FR).
MERLE, Christian; (FR)
Agent: TRECARTIN, Richard, F.; Flehr, Hohbach, Test, Albritton & Herbert L.L.P., Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US)
Priority Data:
08/622,516 25.03.1996 US
Title (EN) CYCLOSPORIN A FORMULATIONS AS NANOPARTICLES
(FR) FORMULATIONS DE CYCLOSPORINE A SOUS FORME DE NANOPARTICULES
Abstract: front page image
(EN)Cyclosporin A formulations are provided as amorphous nanoparticle dispersions for physiologic absorption. The compositions have high bioavailability and patient acceptability. By providing for concentrates comprising lower alkanols and a polyoxyalkylene surfactant as a stable dispersion of cyclosporin A, upon introducing the stable dispersion into an aqueous medium, the subject formulation is produced comprising amorphous bioavailable cyclosporin nanoparticles.
(FR)L'invention se rapporte à des formulations de cyclosporine A sous forme de dispersions nanoparticulaires amorphes destinées à être absorbées physiologiquement. Ces compositions ont une biodisponibilité élevée et sont bien acceptées par les patients. En produisant des concentrés comprenant des alcanols inférieurs et un tensioactif de polyoxyalkylène sous forme d'une dispersion stable de cyclosporine A, lors de l'introduction de cette dispersion stable dans un milieu aqueux, on obtient cette formulation comprenant des nanoparticules de cyclosporine biodisponibles et amorphes.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)